[HTML][HTML] Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
A Ponte-Sucre, F Gamarro, JC Dujardin… - PLoS neglected …, 2017 - journals.plos.org
Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently
needed on a global basis because treatment failure is an increasing problem. Drug …
needed on a global basis because treatment failure is an increasing problem. Drug …
Recent advances and new strategies on leishmaniasis treatment
BM Roatt, JM de Oliveira Cardoso… - Applied Microbiology …, 2020 - Springer
Leishmaniasis is one of the most important tropical neglected diseases according to the
World Health Organization. Even after more than a century, we still have few drugs for the …
World Health Organization. Even after more than a century, we still have few drugs for the …
Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical …
It is important to realize that leishmaniasis guidelines cannot always account for individual
variation among patients. They are not intended to supplant physician judgment with respect …
variation among patients. They are not intended to supplant physician judgment with respect …
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis
TPC Dorlo, M Balasegaram, JH Beijnen… - Journal of …, 2012 - academic.oup.com
Miltefosine is an alkylphosphocholine drug with demonstrated activity against various
parasite species and cancer cells as well as some pathogenic bacteria and fungi. For 10 …
parasite species and cancer cells as well as some pathogenic bacteria and fungi. For 10 …
Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives
F Alves, G Bilbe, S Blesson, V Goyal… - Clinical microbiology …, 2018 - Am Soc Microbiol
Research in visceral leishmaniasis in the last decade has been focused on how better to
use the existing medicines as monotherapy or in combination. Systematic research by …
use the existing medicines as monotherapy or in combination. Systematic research by …
[HTML][HTML] Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis
AS Nagle, S Khare, AB Kumar, F Supek… - Chemical …, 2014 - ACS Publications
Leishmaniasis is a parasitic disease that presents four main clinical syndromes: cutaneous
leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), visceral leishmaniasis/kala azar …
leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), visceral leishmaniasis/kala azar …
An update on pharmacotherapy for leishmaniasis
S Sundar, J Chakravarty - Expert opinion on pharmacotherapy, 2015 - Taylor & Francis
Introduction: Leishmaniasis broadly manifests as visceral leishmaniasis (VL), cutaneous
leishmaniasis (CL) and mucocutaneous leishmaniasis. The treatment of leishmaniasis is …
leishmaniasis (CL) and mucocutaneous leishmaniasis. The treatment of leishmaniasis is …
Chemotherapy of leishmaniasis: present challenges
Cutaneous and visceral leishmaniasis are amongst the most devastating infectious diseases
of our time, affecting millions of people worldwide. The treatment of these serious diseases …
of our time, affecting millions of people worldwide. The treatment of these serious diseases …
Current and emerging medications for the treatment of leishmaniasis
J Chakravarty, S Sundar - Expert opinion on pharmacotherapy, 2019 - Taylor & Francis
Introduction: Leishmaniasis is a vector-borne neglected tropical disease which manifests as
visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucocutaneous …
visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucocutaneous …
Leishmaniasis drug discovery: recent progress and challenges in assay development
Highlights•Leishmaniasis remains a neglected tropical disease, with a high unmet medical
need.•Therapeutic efficacy varies depending on the species of Leishmania parasite.•Leads …
need.•Therapeutic efficacy varies depending on the species of Leishmania parasite.•Leads …